Oric Pharmaceuticals (ORIC) financial statements
Net income was -$129M.
Free cash flow was -$112M.
The diluted share count rose 4963% over the period (dilution).
Income statement
Fiscal years, from Oric Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Research and development | $19M | $23M | $36M | $57M | $62M | $85M | $114M | $110M |
| Selling, general and admin | $3M | $6M | $13M | $22M | $25M | $26M | $29M | $33M |
| Operating income | -$22M | -$29M | -$74M | -$79M | -$92M | -$111M | -$143M | -$143M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$21M | -$27M | -$74M | -$79M | -$89M | -$101M | -$128M | -$129M |
| EPS (diluted) | -$12.32 | -$14.15 | -$3.36 | -$2.07 | -$2.25 | -$1.96 | -$1.83 | -$1.47 |
| Diluted shares | 2M | 2M | 22M | 38M | 40M | 51M | 70M | 88M |
Balance sheet
Fiscal years, from Oric Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $43M | $89M | $294M | $237M | $206M | $208M | $256M | $281M |
| Total current assets | — | $90M | $297M | $241M | $210M | $213M | $262M | $288M |
| Property, plant and equipment | — | $2M | $2M | $2M | $3M | $3M | $3M | $2M |
| Total assets | — | $94M | $299M | $299M | $247M | $252M | $274M | $409M |
| Total current liabilities | — | $5M | $9M | $15M | $15M | $20M | $25M | $20M |
| Total liabilities | — | $6M | $9M | $26M | $25M | $28M | $31M | $25M |
| Shareholders' equity | -$64M | -$90M | $290M | $273M | $222M | $224M | $243M | $384M |
| Net debt | -$43M | -$89M | -$78M | -$226M | -$67M | -$23M | -$59M | -$46M |
Cash flow
Fiscal years, from Oric Pharmaceuticals's 10-K filings with the SEC.
| Fiscal year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$21M | -$24M | -$45M | -$60M | -$75M | -$86M | -$113M | -$111M |
| Capital spending | $525,000 | $768,000 | $667,000 | $939,000 | $2M | $849,000 | $1M | $712,000 |
| Free cash flow | -$21M | -$24M | -$46M | -$60M | -$77M | -$87M | -$114M | -$112M |
| Stock-based compensation | $469,000 | $1M | $5M | $13M | $14M | $15M | $20M | $25M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ORIC.
Open ORIC in InvestinglyQuestions
How much free cash flow does Oric Pharmaceuticals generate?
-$112M in fiscal 2025 (operating cash flow minus capital spending).
From Oric Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.